Squarepoint reports ~5.08% stakes in LENZ
LENZ Therapeutics, Inc. shows multiple Squarepoint entities reporting beneficial ownership stakes in its common stock.
Rhea-AI Filing Summary
LENZ Therapeutics, Inc. shows multiple Squarepoint entities reporting beneficial ownership stakes in its common stock. Squarepoint Ops LLC, Squarepoint Capital LLP, Squarepoint Operations Private Limited and Squarepoint (DIFC) Ltd each report 1,593,246 shares (5.08%). Squarepoint Master Fund Limited reports 1,590,333 shares (5.07%) and Squarepoint Core Master Fund Limited reports 2,913 shares (0.01%).
The filing lists shared voting and shared dispositive power for these holdings and is signed by John Weitzer, Chief Compliance Officer, with signature dates of 04/08/2026.
Positive
- None.
Negative
- None.
Insights
Multiple Squarepoint entities report low-single-digit stakes in LENZ stock, indicating coordinated institutional ownership.
Four Squarepoint affiliates each report 1,593,246 shares representing 5.08% of the class, while a Master Fund reports 1,590,333 shares (5.07%) and a Core Master Fund reports 2,913 shares (0.01%), all with shared voting and dispositive power as of the filing.
Such Schedule 13G filings typically reflect passive institutional positions; subsequent filings would show any change in intent or active engagement. Future SEC forms would show material shifts.
Key Figures
Key Terms
beneficially owned regulatory
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stakes did Squarepoint report in LENZ (LENZ)?
Does the Schedule 13G show voting control by Squarepoint in LENZ?
Who signed the Schedule 13G for the Squarepoint entities?
When would Squarepoint need to change this filing type or update disclosures?
AI-generated analysis. How Rhea-AI works. Not financial advice.